Background: Cases of sustained-virological response (SVR or cure) after an ultra-short duration ( 27 days) of direct-acting antiviral (DAA)-based therapy, despite HCV being detected at end of treatment (EOT), have been reported. Established HCV mathematical models that predict the treatment duration required to achieve cure do not take into account the possibility that the infectivity of virus produced during treatment might be reduced. The aim of this study was to develop a new mathematical model that considers the fundamental and critical concept that HCV RNA in serum represents both infectious virus (V i ) and non-infectious virus (V ni ) in order to explain the observation of cure with ultrashort DAA therapy. Methods: Established HCV models were compared to the new mathematical model to retrospectively explain cure in 2 patients who achieved cure after 24 or 27 days of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin or sofosbuvir plus ribavirin, respectively. Results: Fitting established models with measured longitudinal HCV viral loads indicated that in both cases, cure would not have been expected without an additional 3e6 weeks of therapy after the actual EOT. In contrast, the new model fits the observed outcome by considering that in addition to blocking V i and V ni production (ε~0.998), these DAA þ ribavirin treatments further enhanced the ratio of V ni to V i , thus increasing the log (V ni /V i ) from 1 at pretreatment to 6 by EOT, which led to <1 infectious-virus particle in the extracellular body fluid (i.e., cure) prior to EOT. Conclusions: This new model can explain cure after short duration of DAA þ ribavirin therapy by suggesting that a minimum 6-fold increase of log (V ni /V i ) results from drug-induced enhancement of the V ni / V i .
Introduction
Treatment of chronic hepatitis C virus infection has dramatically improved with >~90% cure (or sustained virological response, SVR) rates using all-oral directeacting-antivirals (DAAs), with shorter treatment and minimal side-effects, relative to interferon-based treatment (WHO, 2015) . Theoretically, cure is achieved when there is less than one virus particle and HCV-infected cell in the body (termed cure boundary) (Dixit et al., 2004; Snoeck et al., 2010) . The typical HCV decline under DAA treatment is biphasic, consisting of a 1st phase rapid virus decline (12e48 h), followed by a slower 2nd phase virus decay . Mathematical modeling of HCV kinetics can reproduce this biphasic viral decline and can estimate the duration of treatment needed to clear the virus (and infected cells) to reach the cure boundary. For example, real-time modeling successfully predicted the duration of interferon-free therapy with silibinin plus ribavirin required to achieve cure (Dahari et al., 2015) . Recently, the cure boundary concept was retrospectively examined using data from 58 HCV genotype-1 infected patients treated for 12 weeks with three different approved sofosbuvir (SOF)-based regimens . Modeling predicted that the majority of patients would reach cure with 8 weeks of therapy, which is in agreement with clinical studies showing high cure rates with 8 weeks of treatment in non-cirrhotic HCV genotype-1 patients (Buggisch et al., 2016; Kowdley et al., 2014; O'Brien et al., 2016) . Moreover, 43% of patients treated with SOF-based regimens were predicted to reach cure within 6 weeks.
We previously observed cure in two patients treated with DAAs for less than 4 weeks, despite having detectable HCV RNA close to end of treatment (EOT) (Hasin et al., 2016; Meissner et al., 2014) . HCV RNA detected at EOT in patients who subsequently develop SVR might be due in part to the presence of non-infectious RNA or virus (V ni ), which has been identified in-vivo in HCV-infected chimpanzees and in-vitro (Feinstone et al., 1981; Major et al., 2002; Sansone et al., 2014) . Further, in vitro inhibition experiments utilizing HCV DAAs directed again NS5A (such as ombitasvir prescribed to patient 1 in this study) have documented a reduction in the infectivity of the virus produced during treatment resulting in an increase in the relative amount of noninfectious particles (V ni ) to infectious particles (V i ) (Sansone et al., 2014) . In the current study we show that established mathematical models cannot explain cure in these two patients and suggest a new model in which the cure boundary is related not to the total viral load in blood, but to the number of infectious viral particles.
Methods

Patients
Viral kinetics were measured from two patients treated in clinical practice who achieved cure after 24 days of paritaprevir, ombitasvir, dasabuvir, ritonavir (PODr) and ribavirin (RBV) (Hasin et al., 2016 ) (patient 1) or 27 days of SOF þ RBV (Meissner et al., 2014) (patient 2).
Mathematical model
Since the standard biphasic and the multiscale (Guedj et al., 2013 ) models (termed established models) would have predicted treatment failure in these cases (Eqs. S1 and S2, Supplementary text), we developed a new extended biphasic model (Fig. 1) , reminiscent of an extended multiscale model presented by Nguyen et al. (2015) , that incorporated assumptions about infectious and non-infectious virus, as shown here:
where V i and V ni represent infectious and non-infectious HCV, respectively. V i infects target cells, T 0 , with constant rate b, generating infected cells, I, which produce new infectious and noninfectious virions at rate p i and p ni per infected cell, respectively. Both V i and V ni are assumed to be cleared at rate c per virion. DAAcontaining regimens such as PODr inhibit HCV replication which effects both V i and V ni production with a constant effectiveness, ε. However, the ability of DAAs (such as NS5A inhibitors (Sansone et al., 2014) ) and RBV (Dahari et al., 2007; Dixit et al., 2004) to alter the infectivity of secreted virus would result in a gradual increase in the ratio of non-infectious to infectious virus, which is modelled by exp(-gt), where g is a constant and t is time post treatment initiation.
Parameter estimation
We assume the target cell (i.e., hepatocyte) level per ml is constant at 1 Â 10 7 cells (Dahari et al., 2007) . Thus, target cell number was kept constant and initial infected cell number is given
represents pre-treatment level of infectious virus. Reverse titration studies in chimpanzees have provided quantification of HCV RNA copy number and infectious titers within HCV-positive samples (Engle et al., 2008; Major et al., 2002) , suggesting a pretreatment ratio of V i and V ni of 1:11 (i.e., p i /p ni ¼ 1/ 11). Thus, we have V i0 ¼ V tot0 =12 where V tot0 is the measured pretreatment HCV level. Employing initial steady state conditions also yields p i ¼ cV i0 =I 0 and p ni ¼ 11p i . Parameter b was set to 7 Â 10 À8 mL/virion/day to target a low fraction of HCV-infected hepatocytes (~4%), consistent with a previously estimated range (Liang et al., 2009 ). Due to lack of frequent sampling in patient 1, especially during the first 2 days of therapy, the effectiveness of PODr þ RBV in blocking HCV production was set to ε ¼ 0.998 as recently estimated (Gambato et al., 2016) and HCV clearance rate was set to c ¼ 6/day . In the SOF þ RBV treated patient (patient 2), the availability of frequent HCV measurements allowed for the estimation of both ε and c parameters.
Cure boundary
The time to eradication of the last infected cell is more speculative due to the lack of experimental data on the infected cell number . Therefore we focused on the viral cure boundary, i.e., <1 virus particle in the extracellular body fluid (approximately 13.5 L) which corresponds to one virion/ 13,500 mL ¼ 7 Â 10 À5 .
Fitting and sensitivity analysis
The available 2 patient datasets were used to estimate unknown parameters of the three models (Eqs. S1 and S2, and Eq. (1)) using fitting procedure lsqnonlin in MATLAB R2016a. The estimation procedure also yields Jacobian matrix and covariates which were then used to determine 95% CI of the estimated parameters using 'nlparci' in MATLAB R2016a (Bates and Watts, 1988) . It should also be noted that the estimated value of parameter g represents a minimum estimate due to the inability to measure Vi. A robustness analysis of the estimated model parameters is further described in the Supplementary text.
Results
Established HCV mathematical models fail to explain cure. The standard model (Eq. S(1)) predicts a time-to-cure for the two cases of 8e10 weeks with an estimated loss of infected cells (d) Table S2 ). Thus, both established models suggested a time-to-cure of at least 4 additional weeks of therapy than what both patients actually received.
A model that accounts for infectious and non-infectious virus can explain cure. The new extended biphasic model ( Fig. 1; Eq. (1)) fits well with measured viral load and predicts cure with ultrashort therapy (Fig. 2) . The new model predicts that DAAs plus RBV not only block HCV production but in addition reduce the infectivity of the virus produced, which is modelled through (Table 1) . Despite the reduced production of infectious virions, the mean loss of infected cells was estimated to be similar as in the standard model (0.278/day vs 0.281/day for patient 1; 0.042/day vs 0.042/day for patient 2) ( Table 1; Table S1 ). The new model can explain a time-to-cure (1) ). In the figure, infected cells (I) produce both infectious virions (V i ) and non-infectious virions (V ni ). Only V i infects target cells, T 0 , with constant rate b, generating infected cells, I, which produce new infectious and non-infectious virions at rate p i and p ni per infected cell, respectively. Both V i and V ni are assumed to be cleared at rate c per virion. DAA-containing regimens such as PODr inhibit HCV replication which effects both V i and V ni production with a constant effectiveness ε but under the effect of some DAAs ± RBV, which alter progeny virion infectivity, there is a time-dependent reduction in secretion of infectious virions relative to noninfectious virions which is modelled through the term exp(-g*t). À5 IU/mL represented by horizontal dotted line) before PODr þ RBV was stopped at day 24 and 27 for P1 and P2 respectively (vertical dotted line), minimum values of parameter g were estimated as 0.366/d and 0.404/d for patient 1 and patient 2 respectively. Pretreatment total viral load, V tot0 was at 2,000,000 IU/mL and 147,910 IU/mL for patient 1 and 2 respectively, as measured before either PODr þ RBV and SOF þ RBV therapy was initiated. Pretreatment infectious virus level V tot0 /12 was assumed in both patients based on empirically measured HCV specific infectivity in chronically infected chimpanzees as explained in Methods. Parameters c ¼ 6/d and ε ¼ 0.998 were kept fixed in patient 1 as explained in Methods while they were estimated at 4.875/d and 0.999 in patient 2.
within 24 days of treatment for patient 1 and 27 days of treatment for patient 2.
Discussion
Established HCV mathematical models were used to predict on treatment (real time) treatment duration needed to achieve cure with silibinin þ RBV (Dahari et al., 2015) , and retrospectively under approved DAAs Gambato et al., 2016) . However, in the current study we showed that these models cannot explain two cases of cure after ultrashort (<4 weeks) DAA therapy. A rapid viral decline was observed in the two cases presented here (HCV RNA levels were <500 IU/mL by day 2 and 7, in patient 2 and 1, respectively). Similarly, a phase 2a study documented cure after 3 weeks of DAA (without ribavirin) therapy in all patients with HCV RNA levels<500 IU/mL by day 2 and suggested that established models failed to predict time-to-cure (Lau et al., 2016) . We developed a new model to explain two ultra-short successful therapy cases that includes infectious (V i ) and non-infectious (V ni ) virions. The new model assumes that in addition to blocking V i and V ni production (ε~0.998), treatment further reduced the infectivity of secreted virus (parameter g 0.372/d) thus increasing the log (V ni / V i ) ratio from 1 at baseline to 6 by EOT. A conceptual implication of the new model is that while HCV RNA (i.e., V i þ V ni ) was detected close to EOT (termed EOTþ), V i reached the cure boundary before EOT.
The main limitation to validating the hypothesized relative change in V i and V ni during DAA therapy (via parameter g in the model) is the inability to measure HCV infectivity (i.e. V i ) in patient samples. However, a reduction in secreted HCV infectivity under NS5A inhibitor treatment has been shown in vitro (Sansone et al., 2014) and proposed for RBV (Dahari et al., 2007; Dixit et al., 2004; Hofmann et al., 2007; Lutchman et al., 2007) . In fact, parameter g in the model would be relevant not only to ribavirin and NS5A inhibitors, but to other drugs or endogenous immune responses that might directly or indirectly alter virion infectivity. For example, restoration of the host immune response (e.g. improved neutralizing antibody response), due to a significant decline in viral burden within 2 days after initiation of DAA treatment, might contribute to the predicted increase in V ni /V i ratio. As suggested for HIV (Conway and Perelson, 2015) , prevention or reversal of T cell exhaustion might result from HCV viral decline under DAA therapy, contributing to viral suppression. Moreover, the host immune response could potentially also increase death/ loss of HCV-infected cells (parameter d in the model), although an increase in death/loss of HCV-infected cells would not increase V ni / V i ratio and thus could not explain cure in the 2 cases presented here. This scenario of enhanced death might lead to complete HCV clearance after treatment was stopped (Meissner et al., 2014; Veerapu et al., 2011) but this is difficult to model due to a lack of supporting data.
In conclusion, we developed a new mathematical model that addresses the fundamental relationship between infectious and non-infectious virions during DAA therapy and explains two cases of HCV cure after an ultra-short treatment (Hasin et al., 2016; Meissner et al., 2014) . The new model has the potential to explain cases of DAA therapy in which established models have failed to predict cure (Lau et al., 2016; Nguyen et al., 2015) . Further studies are needed to confirm whether the new model with a cure boundary based on the eradication of infectious virus (rather than total virus) will be accurate in predicting the duration of DAA therapy needed to achieve cure and the outcomes of ultra-short treatment regimens. 
